Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart for moderately to severely active ulcerative colitis
NL-OMON61086Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing tulisokibart with placebo (2 arms). Primary endpoints: Percentage of participants achieving clinical remission per Modified Mayo Score at Week 12 and Percentage of participants achieving clinical remission per Modified Mayo Score at Week 52. Started Apr 2024; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON61086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61086.